

The 8th International Electronic Conference on Medicinal Chemistry (ECMC 2022) 01–30 NOVEMBER 2022 | ONLINE

Chemiluminescent self-activating photosensitizers for a selective anticancer therapy

Chaired by **DR. ALFREDO BERZAL-HERRANZ**; Co-Chaired by **PROF. DR. MARIA EMÍLIA SOUSA**





C. M. Magalhães^{1,*}, P. Berdullas,^{1,2} J. Esteves da Silva,^{1,2} L. Pinto da Silva^{1,2}


¹Chemistry Research Unit (CIQUP), Faculty of Sciences of University of Porto, R. Campo Alegre 687, 4169-007 Porto, Portugal ²LACOMEPHI, GreenUPorto, Department of Geosciences, Environment and Territorial Planning, Faculty of Sciences, University of Porto, R. Campo Alegre 697, 4169-007 Porto, Portugal

* Corresponding author: up201201533@up.pt



Chemiluminescent self-activating photosensitizers for a selective anticancer therapy

Graphical Abstract






Abstract: Cancer is a challenging disease to treat, regarding treatment efficiency and side-effects. To overcome these problems, extensive studies are exploring therapies with reduced side-effects, such as photodynamic therapy (PDT). PDT has advantages over conventional therapies, however its dependence on light limits it to treating tumors under the skin/ outer lining of organs. We have developed new photosensitizers self-activated intracellularly with tumor-selectivity based on chemiluminescent reactions involving a cancer marker. The photosensitizer is directly chemiexcited to a triplet excited state generating singlet oxygen, without an external light source. Thus, we aimed to develop self-activating photosensitizers which can be used for light-free photodynamic therapy, eliminating its light-related restrictions. Cytotoxicity assays with breast and prostate cell lines showed that the novel photosensitizers possess significant toxicity toward tumor cells, while not affecting normal cells. Besides we compared the activity of these compounds with standard treatments, finding higher cytotoxicity.

Keywords: Anticancer; Chemiluminescence; Self-illuminating; Tumor-selective.


есмс 2022

Cancer was responsible for almost 10 million deaths in 2020 (GLOBOCAN)





Photodynamic therapy (PDT)




Scheme 1. Schematic representation of the mechanisms of action of PDT.


Design PSs that can be activated intracellularly without the need for external light sources




Objectives




Conversion of thermal energy into excitation energy





Objectives



Scheme 2. Chemical structures of synthetized Coelenterazine analogues.



Chemiluminescent/Fluorescent reaction characterization





Figure 1. Chemiluminescence output of CLZ-4 as a function of KO_2 in methanol (**a**). Effect exerted on the fluorescence (I/I_0) of the singlet oxygen sensor, ABDA, as a function of the concentration of compounds (**b**).

ABDA: Fluorescence probe for singlet oxygen production 9,10-Anthracenediylbis(methylene)dimalonic acid

In vitro cytotoxic potential

Prostate cancer cell line (PC-3)



Breast cancer cell line (MCF-7)




Figure 2. Percent viability of PC-3 and MCF-7 cell line measured by MTT reduction assays for CLZ 1-3 (72 h) and CLZ-4 (24h), at increasing concentrations. Percent viability was obtained by comparing with control cell viability, considered as 100%.

In vitro selectivity evaluation in healthy breast cell line (MCF-10A)




Figure 3. Relative viabilities of MCF-7 and MCF-10A cells after 24 h incubation with increasing concentrations of CLZ-4. Percent viability was obtained by comparing with control cell viability, considered as 100%.

In vitro comparison with standard treatment for breast cancer







Figure 4. Percent viability measured by MTT reduction assays for **CLZ-4** (24 h) and **tamoxifen**, at increasing concentrations. Percent viability was obtained by comparing with control cell viability, considered as 100%.









Chemiluminescent reaction characterization





Figure 5. Normalized chemiluminescence output of OH-, Cl-, and Br-Cla in DMF-acetate buffer pH 5.14 (0.68%) (a). Chemiluminescence intensity of OH-, Cl-, and Br-Cla in the presence of 20 mg of KO_2 in metanol (b).

In vitro cytotoxic potential

Colon cancer cell line (HT-29)








Figure 6. Effect of OH-, Cl-, and Br-Cla on HT-29 cell viability. Cells were cultured in the presence of increasing concentrations of each compound. After 48 h, an MTT assay as performed to measured cellular viability. Results are presented as mean \pm SEM. * Statistically significant vs. control at p< 0.05; **** statistically significant vs. control at p< 0.001.

In vitro cytotoxic potential

Neuroblastoma cell line (SH-SY5Y)




Figure 7. Effects of OH-, Cl-, and Br-Cla on SH-SY5Y cellular viability. Cells were cultivated in the presence of increasing concentrations of each compound. After 48 h, an MTT assay was performed to measure cellular viability. Results are presented as mean \pm SEM. * Statistically significant vs. control at p< 0.05; **** statistically significant vs. control at p< 0.0001.

In vitro cytotoxic potential

Neuroblastoma cell line (SH-SY5Y)




Figure 7. Effects of OH-, Cl-, and Br-Cla on SH-SY5Y cellular viability. Cells were cultivated in the presence of increasing concentrations of each compound. After 48 h, an MTT assay was performed to measure cellular viability. Results are presented as mean \pm SEM. * Statistically significant vs. control at p< 0.05; **** statistically significant vs. control at p< 0.0001.

Conclusions

- New Coelenterazine derivatives (heavy atom effect)
 were designed and synthesized for improving PDT
- Intracellular self-activation (superoxide anion), in the absence of light
- Selectivity to cancer cells, inducing significant cytotoxicity in different tumor cell lines, even higher than reference drugs
- Pathway for eliminating the light related restrictions that PDT presents.



ECMC 2022

Acknowledgments

- FCT for the PhD grant (SFRH/BD/143211/2019)
- Supervisor Prof. Dr. Luís Pinto da Silva
- Co-supervisor Prof. Dr. Joaquim Esteves da Silva
- Dr. Patricia González-Berdullas
- Projects PTDC/QUI-QFI/2870/2020 and UIDB/00081/2020
- Nuno Vale, responsible for *in vitro* cytotoxicity in cancer cell lines study



